IceCure Medical Ltd (ICCM)
| Market Cap | 10.35M -82.1% |
| Revenue (ttm) | 3.95M +41.6% |
| Net Income | -16.88M |
| EPS | -6.66 |
| Shares Out | 3.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,658 |
| Open | 3.040 |
| Previous Close | 3.000 |
| Day's Range | 2.960 - 3.200 |
| 52-Week Range | 2.120 - 42.000 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 22.67 (+650.66%) |
| Earnings Date | Aug 12, 2026 |
About ICCM
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncolo... [Read more]
Financial Performance
In 2025, IceCure Medical's revenue was $3.38 million, an increase of 2.67% compared to the previous year's $3.29 million. Losses were -$15.06 million, -1.70% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price target is $22.67, which is an increase of 650.66% from the latest price.
News
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical t...
IceCure Medical Earnings Call Transcript: Q2 2026
Revenue grew 45% year-over-year to $1.8 million in H1 2026, driven by increased system sales and probe utilization, with the U.S. install base expanding 70%. Gross margin improved despite FX headwinds, and the company ended H1 with $12 million in cash.
IceCure Medical Earnings release: Q2 2026
IceCure Medical released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
The Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("...
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
Adventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approval The site will be led by breast surgeon, Dr. Dennis Ho...
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroy...
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
The petition by The Society of Interventional Oncology (SIO) includes adding criteria for patients aged 50-69 who are poor surgical candidates or who decline surgery in the National Comprehensive Canc...
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CA...
IceCure Medical expands U.S. commercial team for ProSense cryoablation
IceCure Medical (ICCM) announced the expansion of its United States sales and marketing teams. In response to demand from leading hospitals and physicians across the country, the company has strengthe...
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
CAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation ...
IceCure Medical Slides: Investor presentation
IceCure Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
IceCure Medical highlights expanding commercial adoption of ProSense
IceCure Medical (ICCM) highlighted the growing international interest in its ProSense system in Brazil at the Simposio de Radiologia Intervencionista em Oncologia. “IceCure’s ProSense(TM) holds Agenci...
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer ...
IceCure Medical registers to sell 5.5M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.5M ordinary shares. The company is not selling any shares under…
IceCure Medical regains compliance with Nasdaq minimum bid price requirement
IceCure Medical (ICCM) received written notice from Nasdaq indicating that the company has regained compliance with the minimum bid price requirement which requires listed securities to maintain a min...
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Medical Registration statement: Registration filing
IceCure Medical filed a registration statement on June 25, 2026, providing details about a securities offering with the SEC.
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals , the article highlights strong clinical outcomes with ProSense® cryoablation and describes ...
Icecure Medical Ltd trading resumes
09:55 EDT Icecure Medical (ICCM) Ltd trading resumes
Icecure Medical Ltd trading halted, volatility trading pause
09:45 EDT Icecure Medical (ICCM) Ltd trading halted, volatility trading pause
Why Is IceCure Medical Stock (ICCM) Up Today?
IceCure Medical stock was up alongside new medical device progress and positive analyst comments.
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Medical business ‘moving in the right direction,’ says Brookline
Brookline tells investors in a research note that IceCure Medical’s (ICCM) disclosure of a 70% boost in the U.S. active commercial install base of ProSense for breast cancer cryoablation is…
IceCure Medical reports increase in ProSense use for breast cancer cryoablation
IceCure Medical (ICCM) reported a 70% increase in its U.S. active commercial install base of ProSense for breast cancer cryoablation following FDA marketing authorization in October 2025, reflecting a...
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences co...